Serum galectin-3: A risk factor for vascular complications in type 2 diabetes mellitus

Chinese Medical Journal

Volumn 126, Issue 11, 2013, Pages 2109-2115

  Jin, Qi Hui ^a   Lou, Yu Feng ^b   Li, Tian Lang ^a   Chen, Huai Hong ^a   Liu, Qiang ^a   He, Xiao Jun ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Galectin 3; Type 2 diabetes mellitus; Vascular complications

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; FIBRINOGEN; GALECTIN 3; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMINURIA; ANGINA PECTORIS; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CROSS-SECTIONAL STUDY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ELISA KIT; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RETINOPATHY; RISK FACTOR; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84878683637     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130217     Document Type: Article

References (36)

1. Cooper ME, Gilbert RE, Jerums G. Diabetic vascular complications. Clin Exp Pharmacol Physiol 1997; 24: 770-775.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
3. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
4. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care 1993; 16: 1022-1025.
5. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009; 94: 3171-3182.
6. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272: 55-64.
7. Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011; 24: 905-913.
8. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012; 58: 267-273.
9. Rabinovich GA, Rubinstein N, Toscano MA. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta 2002; 1572: 274-284.
10. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11: 811-817.
11. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010; 99: 323-328.
12. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-1224.
13. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol 2009; 130: 83-88.
14. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008; 172: 247-255.
15. Canning P, Glenn JV, Hsu DK, Liu FT, Gardiner TA, Stitt AW. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res 2007; 2007: 51837.
16. Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, et al. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004; 18: 1773-1775.
17. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol 2009; 130: 83-88.
18. Henderson NC, Sethi T. The regulation of inflammation bygalectin-3. Immunol Rev 2009; 230: 160-171.
19. Report of a WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization, 1999 Geneva.
20. Diabetic Retinopathy Study Research Group. DRS report no. 3: Four risk factors for severe visual loss in diabetic retinopathy. Arch Ophthalmol 1979; 97: 654-655.
21. Shirwany NA, Zou MH. Vascular inflammation is a missing link for diabetes-enhanced atherosclerotic cardiovascular diseases. Front Biosci 2012; 17: 1140-1164.
22. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
23. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176.
24. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, et al. Microalbuminuria and potential confounders: a review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18: 572-581.
25. Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Ser World Health Organ 1968; 56: 1-188.
26. Gornik HL, Beckman JA. Peripheral arterial disease. Circulation 2005; 111: e169e72.
27. Berni A, Giuliani A, Tartaglia F, Tromba L, Sgueglia M, Blasi S, et al. Effect of vascular risk factors on increase in carotid and femoral intima-media thickness. Identification of a risk scale. Atherosclerosis 2011; 216: 109-114.
28. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 1404-1411.
29. Xu Y, Whitmer K. C-reactive protein and cardiovascular disease in people with diabetes: high-sensitivity CRP testing can help assess risk for future cardiovascular disease events in this population. Am J Nurs 2006; 6: 66-72.
30. Schöttker B, Herder C, Müller H, Brenner H, Rothenbacher D. Clinical utility of creatinine-and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes. Diabetes Care 2010; 35: 879-886.
31. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003; 26: 2081-2087.
32. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011; 108: 385-390.
33. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008; 13: e17-39.
34. Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011; 24: 905-913.
35. Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron MG. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol 2002; 168: 1813-1822.
36. Suzuki Y, Inoue T, Yoshimaru T, Ra C. Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitochondrial permeability transition. Biochim Biophys Acta 2008; 1783: 924-934.